UCSF is currently conducting 39 ovarian cancer clinical trials, with 16 open to eligible patients, testing everything from targeted therapies to immunotherapy and new oral medicines for advanced disease. For people diagnosed with ovarian cancer, these trials represent a significant expansion in treatment options beyond traditional chemotherapy. The research spans multiple approaches, including studies specifically designed for people with BRCA mutations and programs focused on improving quality of life after treatment .

What Types of Ovarian Cancer Treatments Are Being Tested?

UCSF's ovarian cancer research portfolio covers several distinct treatment strategies. Researchers are evaluating targeted therapies that attack specific genetic mutations, immunotherapy approaches that help the body's immune system fight cancer cells, and new oral medications that patients can take at home rather than through infusions. The trials also include studies on supportive care delivery models and wellness programs for cancer survivors, recognizing that treatment extends beyond the initial diagnosis .

One notable trial is examining a combination of two drugs, avutometinib and defactinib, for people with recurrent low-grade serous ovarian cancer who have already been treated with platinum-based chemotherapy. Another study is investigating a first-in-class treatment called CLSP-1025, which targets a specific genetic mutation called p53 R175H found in some solid tumors. Additionally, researchers are testing STX-478, a new drug being evaluated both as a single treatment and in combination with other cancer medications for people with advanced solid tumors .

Are There Trials Specifically for People With BRCA Mutations?

Yes, UCSF is conducting specialized research for people carrying BRCA1 mutations, who face significantly higher risks of ovarian cancer. One important trial is comparing two surgical approaches to reduce ovarian cancer risk in women with BRCA1 mutations aged 35 to 50. The study evaluates bilateral salpingectomy, which involves removing the fallopian tubes, against bilateral salpingo-oophorectomy, which removes both the fallopian tubes and ovaries. This research aims to help doctors determine whether these two procedures are equally effective at reducing cancer risk, potentially offering women more surgical options .

Additionally, people with BRCA mutations are not excluded from other ovarian cancer trials at UCSF. For example, in a study testing carboplatin combined with mirvetuximab soravtansine for advanced ovarian cancer, patients with BRCA mutations are allowed to participate and can receive standard maintenance therapy including bevacizumab and PARP inhibitors alongside the trial treatment .

How to Determine If You're Eligible for an Ovarian Cancer Clinical Trial

• Age Requirements: Most UCSF ovarian cancer trials are open to adults aged 18 and older, though some specialized studies have specific age ranges, such as the BRCA1 surgical comparison trial limited to women aged 35 to 50.
• Disease Stage and History: Different trials target different patient populations, including those with newly diagnosed advanced-stage disease, recurrent cancer that has progressed after prior treatment, and solid tumors with specific genetic mutations.
• Genetic Testing: Some trials require genetic testing to confirm eligibility, such as the carboplatin-mirvetuximab study, which tests tumors for FRα receptor expression to identify appropriate candidates.
• Prior Treatment Status: Certain trials are designed for people who have already received specific treatments, such as platinum-based chemotherapy, while others are for newly diagnosed patients who have not yet started treatment.
• Location Access: Trials are conducted at UCSF's San Francisco location and other participating centers, so geographic accessibility may affect your options.

To learn whether you qualify for a specific trial, contact UCSF's clinical trials office directly or discuss trial eligibility with your oncologist, who can review your medical history, test results, and current health status .

What About Support Beyond Medical Treatment?

UCSF recognizes that ovarian cancer care extends beyond chemotherapy and surgery. The institution is conducting trials focused on supportive care delivery models and survivor wellness programs. One study compares a technology-based supportive cancer care approach with a redesigned team-based model to determine which approach better meets patients' needs. Another trial, called "Tools To Be Fit," examines how different intervention components affect body weight, nutrition, and physical activity in cancer survivors. Research indicates that cancer survivors whose nutrition and physical activity habits align with American Cancer Society guidelines may experience longer disease-free survival .

These supportive care trials acknowledge an important reality: completing cancer treatment is not the end of the journey. Many survivors struggle with fatigue, weight changes, and lifestyle adjustments. By testing different support models and wellness interventions, UCSF aims to identify the most effective ways to help people thrive after treatment .

Why Should You Consider Participating in a Clinical Trial?

Clinical trials offer several potential benefits. Participants gain access to cutting-edge treatments that may not yet be widely available, receive close medical monitoring, and contribute to research that advances treatment options for future patients. For ovarian cancer specifically, where treatment options remain limited compared to some other cancers, trials can provide hope and new possibilities. Additionally, many trials offer supportive care services and wellness programs that enhance quality of life during and after treatment .

If you or a loved one has been diagnosed with ovarian cancer, discussing clinical trial options with your healthcare team is an important step. UCSF's extensive portfolio of 39 active trials demonstrates the institution's commitment to advancing ovarian cancer care and offering patients access to the latest scientific innovations.